

# 26th Annual Alzheimer Day

## Research Satisfaction Survey

Brittanie Muse, MSPH; Alexis Menias; Robert Shepard; Sandra Weintraub, PhD; Daniel Lee, MD;  
Joshua Cahan, MD; Ian Grant, MD

Northwestern University Mesulam Center for Cognitive Neurology & Alzheimer's Disease

[brittanie.muse@northwestern.edu](mailto:brittanie.muse@northwestern.edu)

## Research Satisfaction Survey

The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study is a prevention trial aimed at treating amyloid-positive but otherwise healthy individuals (aged 65-85) at risk for developing Alzheimer's disease (AD). Cognitively-normal individuals were screened for amyloid burden in their brains (via PET scan). Those with positive amyloid PET scans were enrolled into the study and are currently being treated with an anti-amyloid antibody (Solanezumab) or placebo. Currently, participants are expected to be followed in this study for up to 7.5 years.

Maintaining participant satisfaction with research is important to ensure the success of a trial, especially studies that span as many years as the A4 study. Researchers depend on the voluntary participation and compliance of research subjects to collect enough data that can inform possible medical treatments. At regular intervals during the A4 study, participants complete 8-question surveys to determine their satisfaction with the research study. This provides us with critical feedback about conducting trials on Alzheimer's and related disorders where treatments require months or years to show effectiveness.

Through almost 5 years of participation (240 weeks), all participants have rated the quality of tests and attention they've received during the study as good or excellent. All participants have regularly stated that most or all of their expectations about the study have been met. All participants have said they would recommend this research program to a friend. All participants regularly stated the things they liked best about the study were volunteering, interacting with staff, feedback on how they were doing, and raising awareness.

*This research was presented as part of the 26th Annual Alzheimer Day hosted by the Northwestern University Mesulam Center for Cognitive Neurology and Alzheimer Disease on September 24, 2020.*

[brain.northwestern.edu](http://brain.northwestern.edu)